CA2544227A1 - Food product containing policosanols - Google Patents
Food product containing policosanols Download PDFInfo
- Publication number
- CA2544227A1 CA2544227A1 CA002544227A CA2544227A CA2544227A1 CA 2544227 A1 CA2544227 A1 CA 2544227A1 CA 002544227 A CA002544227 A CA 002544227A CA 2544227 A CA2544227 A CA 2544227A CA 2544227 A1 CA2544227 A1 CA 2544227A1
- Authority
- CA
- Canada
- Prior art keywords
- sugar cane
- cane juice
- cholesterol
- policosanol
- juice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 33
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 82
- 240000000111 Saccharum officinarum Species 0.000 claims abstract description 77
- 235000007201 Saccharum officinarum Nutrition 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 41
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 7
- 229960001109 policosanol Drugs 0.000 claims description 55
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 55
- 238000008214 LDL Cholesterol Methods 0.000 claims description 22
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 240000002234 Allium sativum Species 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 244000134552 Plantago ovata Species 0.000 claims description 5
- 235000003421 Plantago ovata Nutrition 0.000 claims description 5
- 239000009223 Psyllium Substances 0.000 claims description 5
- 229930182558 Sterol Natural products 0.000 claims description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 5
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 235000013734 beta-carotene Nutrition 0.000 claims description 5
- 239000011648 beta-carotene Substances 0.000 claims description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 5
- 229960002747 betacarotene Drugs 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 239000003086 colorant Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000003925 fat Substances 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000019634 flavors Nutrition 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 235000010855 food raising agent Nutrition 0.000 claims description 5
- 235000004611 garlic Nutrition 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 235000012661 lycopene Nutrition 0.000 claims description 5
- 229960004999 lycopene Drugs 0.000 claims description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 5
- 239000001751 lycopene Substances 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 229940070687 psyllium Drugs 0.000 claims description 5
- 229940026314 red yeast rice Drugs 0.000 claims description 5
- 239000003381 stabilizer Substances 0.000 claims description 5
- 150000003432 sterols Chemical class 0.000 claims description 5
- 235000003702 sterols Nutrition 0.000 claims description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 5
- -1 flavenols Chemical class 0.000 claims description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 4
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 4
- 239000006014 omega-3 oil Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 235000011962 puddings Nutrition 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 235000014510 cooky Nutrition 0.000 claims description 3
- 235000021185 dessert Nutrition 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 235000013882 gravy Nutrition 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 235000014594 pastries Nutrition 0.000 claims description 3
- 235000015108 pies Nutrition 0.000 claims description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 2
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 2
- 235000012970 cakes Nutrition 0.000 claims description 2
- 235000013325 dietary fiber Nutrition 0.000 claims description 2
- 235000012489 doughnuts Nutrition 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 235000021067 refined food Nutrition 0.000 claims description 2
- 235000015067 sauces Nutrition 0.000 claims description 2
- 235000015094 jam Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 101
- 235000012000 cholesterol Nutrition 0.000 abstract description 41
- 230000002354 daily effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 10
- 102000007330 LDL Lipoproteins Human genes 0.000 description 9
- QOEHNLSDMADWEF-UHFFFAOYSA-N I-Dotriacontanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO QOEHNLSDMADWEF-UHFFFAOYSA-N 0.000 description 8
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 8
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 8
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 6
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 6
- 229960002666 1-octacosanol Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 4
- 229960000903 pantethine Drugs 0.000 description 4
- 235000008975 pantethine Nutrition 0.000 description 4
- 239000011581 pantethine Substances 0.000 description 4
- 229940068065 phytosterols Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 239000006057 Non-nutritive feed additive Substances 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 229940077731 carbohydrate nutrients Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229960003512 nicotinic acid Drugs 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PKBSGDQYUYBUDY-UHFFFAOYSA-N 1-nonacosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCO PKBSGDQYUYBUDY-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010022562 Intermittent claudication Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229960005110 cerivastatin Drugs 0.000 description 2
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- ULCZGKYHRYJXAU-UHFFFAOYSA-N heptacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCO ULCZGKYHRYJXAU-UHFFFAOYSA-N 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- LVXORIXZNUNHGQ-UHFFFAOYSA-N octacosanal Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC=O LVXORIXZNUNHGQ-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000019384 rice bran wax Nutrition 0.000 description 2
- 239000004170 rice bran wax Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940123324 Acyltransferase inhibitor Drugs 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 240000003890 Commiphora wightii Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002404 acyltransferase inhibitor Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 229940107218 chromium Drugs 0.000 description 1
- 235000012721 chromium Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 235000021581 juice product Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000037209 prostate health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention provides a novel composition and method for reducing "bad"
cholesterol and increasing "good" cholesterol. The composition of the invention comprises a food product having sugar cane juice. The sugar can juice preferably contains policosanols. A method of preventing or treating cardiovascular disease comprising administering a composition comprising sugar cane juice is also provided.
cholesterol and increasing "good" cholesterol. The composition of the invention comprises a food product having sugar cane juice. The sugar can juice preferably contains policosanols. A method of preventing or treating cardiovascular disease comprising administering a composition comprising sugar cane juice is also provided.
Description
FOOD PRODUCT CONTAINING POLICOSANOLS
FIELD OF INVENTION
[0001] The present invention relates to food products containing natural ingredients that promote health, particularly cardiovascular health.
FIELD OF INVENTION
[0001] The present invention relates to food products containing natural ingredients that promote health, particularly cardiovascular health.
[0002] BACKGROUND OF THE INVENTION
[0003] Cardiovascular disease is a leading cause of mortality and morbidity in industrialized nations. Elevated low density lipoprotein-cholesterol (LDL) levels is a major risk factor for cardiovascular disease. While various pharmaceutical agents have been developed that lower cholesterol, there are increasing concerns regarding their use. For example, the popular cholesterol lowering drug, Baycol (cerivastatin) was withdrawn from the market after numerous deaths were associated with its use. As a result, there is an increasing demand for alternatives to prescription drugs. Several natural supplements, such as niacin, inositol hexaniacinate, gugulipid and pantethine have been shown to be effective in lowering cholesterol levels.
Niacin has been shown to lower total cholesterol and LDL cholesterol while at the same time raising the level of the "good" HDL cholesterol. However, niacin can cause undesirable side effects such as skin flushing, stomach irritation, nausea, glucose intolerance, visual disturbances and liver damage.
Gugulipid, also known as gugul is an extract from the myrrh tree. Gugulipid increases the breakdown of LDL cholesterol in the liver thereby lowering LDL
levels. It has also been shown to increase HDL cholesterol. A side effect of using gugulipid extract, however, is mild abdominal discomfort. Pantethine is a form of pantothenic acid (vitamin B5) that has also been shown to lower cholesterol. It reduces levels of LDL and total cholesterol, and raises HDL
levels. Pantethine appears to work by improving fat metabolism and by slowing down production of cholesterol in the liver.
Niacin has been shown to lower total cholesterol and LDL cholesterol while at the same time raising the level of the "good" HDL cholesterol. However, niacin can cause undesirable side effects such as skin flushing, stomach irritation, nausea, glucose intolerance, visual disturbances and liver damage.
Gugulipid, also known as gugul is an extract from the myrrh tree. Gugulipid increases the breakdown of LDL cholesterol in the liver thereby lowering LDL
levels. It has also been shown to increase HDL cholesterol. A side effect of using gugulipid extract, however, is mild abdominal discomfort. Pantethine is a form of pantothenic acid (vitamin B5) that has also been shown to lower cholesterol. It reduces levels of LDL and total cholesterol, and raises HDL
levels. Pantethine appears to work by improving fat metabolism and by slowing down production of cholesterol in the liver.
[0004] Another natural product that has been shown to be very effective in reducing LDL and total cholesterol levels is policosanol. Policosanol is a mixture of higher primary aliphatic alcohols. It consists mainly of octacosanal (CH3-CH2 (26) -CH2-OH), triacontanol, and hexacosanol. It also includes other -I -alcohols, namely tetracosanol, heptacosanol, nonacosanol, dotriacontanol, and tetratriacontanol. There are several medical studies showing that policosanol can reduce both total cholesterol and LDL ("bad") cholesterol by about 10-20%. Some studies also suggest that treatment with policosanol results in an elevation of HDL ("good") cholesterol. There is some evidence that policosanol may inhibit coenzyme A(HMG-CoA) reductase. In addition, LDL binding, internalization, and degradation are significantly increased after policosanol treatment. Policosanol is typically derived from sugar cane wax, although it may also be derived from beeswax. The constituent alcohols may vary depending on the source of the policosanol.
[0005] The beneficial effects of policosanol on cholesterol levels have been recognized for some time. United States Patent No. 5,952,393 is directed to a composition for reducing serum cholesterol in humans and animals. The composition includes phytosterol and policosanol in a tablet or soft gelatin capsule formulation. The policosanol is derived from rice bran wax. United States Patent No. 6,565,896 discloses a cholesterol treatment composition comprising: Green Tea extract, Gamma Oryzanol, Gugulipids, Beta Sitosterol, Artichoke extract, Grape Seed extract, Chromium, Pantethine, and Policosanol. United States Patent Application US 2005/0002992 discloses a food or beverage that contains a human metabolic supplement that will enhance human metabolism. The supplement comprises ingredients selected from the group consisting of policosanol, aspartate, lipoic acid, huperzine, trimethylglycine, and medium chain tryglycerides. The policosanol used in the food or beverage is an extracted, dried supplement derived from sugar cane wax.
[0006] In addition to improving serum lipid profiles, policosanol also reduces several other cardiovascular disease risk factors. It has been shown to reduce LDL oxidation, platelet aggregation, endothelial cell damage, and smooth muscle proliferation. It is also effective in patients with intermittent claudication. Policosanol has also been shown to have beneficial effects on other diseased states such as type 2 diabetes, prostate cancer, and inflammation. It has also been shown to promote vascular wall function and structure as well as the function of nerve growth factors and neurotrophic factors. Policosanol can also be used as an agent to suppress toxic metal ionic effects and to normalize or maintain methyl metabolism in the body.
Furthermore, a role for policosanol has been shown to enhance or maintain brain function, nerve function, liver function, bone health, joint health, prostate health, fetal development, postnatal breast milk production, eye health and physical performance.
Furthermore, a role for policosanol has been shown to enhance or maintain brain function, nerve function, liver function, bone health, joint health, prostate health, fetal development, postnatal breast milk production, eye health and physical performance.
[0007] While various types of policosanol tablets or capsules are available, there remained an unmet need for a totally natural source of policosanol and food products containing that policosanol.
SUMMARY OF THE INVENTION
SUMMARY OF THE INVENTION
[0008] The present invention provides a novel type of health food product that contains sugar cane juice. The sugar cane juice contains policosanol. The sugar cane juice is preferably extracted at a temperature below 150 C, more preferably less than 110 C, most preferably less than 105 C.
[0009] In another aspect of the invention, a method of decreasing total cholesterol and low density lipoprotein (LDL cholesterol) is provided. The method of the invention also increases HDL levels. The method comprises administering the equivalent of one teaspoon of sugar cane juice per day for several weeks. As used herein the terms "administering" and "administer"
encompass self-administration or ingestion. The sugar cane juice may be provided in a variety of food products such as candies, puddings, beverages, and the like. Alternatively, straight sugar cane juice may be administered to the subjects.
encompass self-administration or ingestion. The sugar cane juice may be provided in a variety of food products such as candies, puddings, beverages, and the like. Alternatively, straight sugar cane juice may be administered to the subjects.
[0010] In one aspect of the invention, a method of lowering LDL-cholesterol is provided. The method comprises administering to a mammal a daily dose of at least 1 g of sugar cane juice for at least one week. The method preferably comprises administering to a mammal a daily dose of at least 2 g, preferably at least 4 g of sugar cane juice for at least two weeks, more preferably four weeks. In a particularly preferred embodiment, about 5 g of sugar cane juice containing at least 50 mg of policosanol is ingested.
[0011] In a preferred embodiment, the sugar cane juice is provided in a composition comprising at least one additional agent selected from the group consisting of: amino acids, carbohydrates, vitamins, minerals, fats (preferably polyunsaturated fatty acids, more preferably omega-3 fatty acids), flavenols, sterols, psyllium, garlic, gugulipid, anti-oxidants, folic acid, beta-carotene, lycopene, red yeast rice extract, natural and synthetic flavors, colors, preservatives, stabilizers, emulsifiers, leavening agents and other processing aids. Combinations of additional additives may be included. In a preferred embodiment, the additional agent is a phytosterol. In a further preferred embodiment, the phytosterol is present in an amount from about 0.01 to about 20 g per day, preferably about 0.1 to 1.0 g/day.
[0012] In a preferred embodiment of the method, the sugar cane juice is provided for oral consumption in a food product selected from the group consisting of cake, cookie, confectionary, energy bar, pudding, yogurt, frozen dessert, pie, pastry, chewing gum, sauces, gravies, beverages including alcoholic beverages, and other processed foods. The invention applies to any application wherein sugar or another sweetener can be replaced by sugar cane juice containing policosanols. A preferred daily dose of sugar cane juice comprises at least I mg of policosanol. The daily dose is preferably administered for at least 4 weeks, more preferably for at least six weeks.
[0013] In a preferred embodiment, the sugar cane juice comprises from about 1 to about 100 mg of policosanol per 5 g of juice.
[0014] In an alternative embodiment, the sugar cane juice is provided in a format for intravenous administration.
[0015] In another aspect of the invention a food product is provided that comprises sugar cane juice having at least 1 mg policosanol per 5 g of sugar cane juice.
[0016] In one embodiment of the invention, the food product comprises an additional agent selected from the group consisting of: amino acids, carbohydrates, vitamins, minerals, fats (preferably polysaturated fatty acids, more preferably omega-3 fatty acids), flavenols, sterols, psyllium, garlic, gugulipid, anti-oxidants, folic acid, beta-carotene, lycopene, red yeast rice extract, natural and synthetic flavors, colors, preservatives, stabilizers, emulsifiers, leavening agents and other processing aids. Combinations of additional additives may be included. In a preferred embodiment, the additional agent is a phytosterol. In a further preferred embodiment, the phytosterol is present in an amount from about 0.01 to about 20 g per day, preferably about 0.1 to 5.0 g/day.
[0017] A further aspect of the invention provides for the use of sugar cane juice as an agent for the treatment or prevention of cardiovascular disease.
The sugar cane juice typically comprises at least 5 mg policosanol per 5 g juice.
The sugar cane juice typically comprises at least 5 mg policosanol per 5 g juice.
[0018] This summary of the invention does not necessarily describe all features of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] These and other features of the invention will become more apparent from the following description in which reference is made to the appended drawings wherein:
[0020] FIGURE 1 illustrates the mean cholesterol for the base line and treatment groups;
[0021] FIGURE 2 illustrates graphically the mean HDL cholesterol for the base line and treatment groups;
[0022] FIGURE 3 displays graphically the mean LDL cholesterol for the base line and treatment scores.
DETAILED DESCRIPTION
DETAILED DESCRIPTION
[0023] There is a growing demand for functional foods that couple health benefits with good taste. In particular, consumers are demanding healthier snackfoods.
[0024] The present invention provides a food product comprising sugar cane juice as a source of policosanols. Policosanols are normally derived from sugar cane wax or beeswax. They have also previously been isolated from rice bran wax. All the previous sources were waxy substances. The policosanols are extracted through a series of steps and purified. Contrary to popular belief, the present inventors found the surprising result that sugar cane juice prepared without excess heating also contains therapeutically relevant levels of policosanol. The results of the analysis of one sample of sugar cane juice are discussed in Example 1 below. Sugar cane juice provides an all-natural source of unrefined policosanols that have proven health benefits. Using sugar cane juice as a source of policosanois provides the added advantage of providing an all-natural sweetener. This provides for a food product that combines good taste and heart-healthy supplements.
[0025] The invention also provides a method for the treatment or prevention of cardiovascular disease. As discussed further in Example 2 below and as illustrated in the attached Figures, total cholesterol and LDL cholesterol were significantly reduced in patients that ingested sugar cane juice containing policosanois on a daily basis. Mean HDL cholesterol was also increased.
[0026] Daily ingestion of about 0.1 to 20 g of sugar cane juice containing about 0.1 to 2000 mg policosanol is recommended. The sugar cane juice may be administered alone. Preferably, the sugar cane juice is incorporated into a snack food or beverage.
[0027] Policosanol is a term that refers to a group of natural products composed of various fatty alcohols. The food product according to this invention is especially a functional food, a nutritional supplement, a pharma food, a health food, a designer food, or any food product. A suitable amount of policosanol in the food product is from about 1 to 2000 mg of policosanols per serving. The functional food according to this invention can for example be in the form of candy, cookie, cake, chewing gum, yogurt, frozen dessert, or jelly, jams, pastry, pie filling, donuts, pudding, a beverage or the like.
Other foods such as cereals, soups, gravies and prepared meals containing sugar cane juice as a source of policosanols are also encompassed. Any application where sugar cane juice can be used as a source of sugar is within the scope of the invention. This includes formulations for intravenous administration.
Other foods such as cereals, soups, gravies and prepared meals containing sugar cane juice as a source of policosanols are also encompassed. Any application where sugar cane juice can be used as a source of sugar is within the scope of the invention. This includes formulations for intravenous administration.
[0028] The food product of the invention comprising policosanol-containing sugar cane juice may also include other nutritional components. For example, dietary fiber and protein may be included in the food formulation. Other possible components include amino acids, carbohydrates, vitamins, minerals, fats, flavenols, sterols, psyllium, garlic, gugulipid, anti-oxidants, folic acid and the like. The composition may also include polyunsaturated fatty acids, particularly omega-3 fatty acids. Nutraceuticals such as beta-carotene, lycopene, and red yeast rice extract, etc. may be included. This includes any substance that is a food or a part of a food and provides medical or health benefits, including the prevention and treatment of disease. Such products may range from isolated nutrients, dietary supplements, herbal products, genetically engineered designer foods, stimulant functional foods or pharma foods.
[0029] Additional ingredients that may be incorporated include natural and synthetic flavors, colors, preservatives and stabilizers. To obtain a desired consistency, other agents such as emulsifiers, leavening agents and other processing aids may be included.
[0030] In one preferred embodiment, a food product comprising policosanol-containing sugar cane juice further comprises another cholesterol lowering agent. This includes an agent that reduces cholesterol adsorption, an agent that inhibits cholesterol biosynthesis and/or an agent that increases cholesterol metabolism.
[0031 ] One example of a preferred agent for use in the food product is phytosterol. Phytosterols are steroids derived from plants, yeast or fungi.
They are preferably obtained from whole plants or parts thereof such as leaves, stalks, roots, shoots, rhizomes, fruits, kernels, husks, etc.
Naturally occurring compositions or extracts may be used. The term "phytosterol" is used herein to refer to plant sterols and plant stanols that differ from cholesterol in that the side chain at position 17 contains a double bond and/or an additional methyl, ethyl or ethylidene group. The term also encompasses any analogues, derivatives or combinations thereof.
[0032] Phytosterols are similar to cholesterol and compete with cholesterol to get absorbed into the body. In the present invention, the phytosterols may be combined with lecithin to enhance their solubility and absorption. A mixture of more than one phytosterol may be included. In one embodiment, the phytosterol is one that reduces cholesterol absorption in the intestine. In another embodiment, the phytosterol inhibits cholesterol biosynthesis. An exemplary phytosterol composition for use in the present invention could comprise a composition that inhibits the enzyme, 3-hydroxy-3-methylguaryl coenzyme A reductase (HMG+CoA reductase). In yet another embodiment, a phytosterol composition capable of increasing cholesterol metabolism is provided. The phytosterol increases the conversion of cholesterol into bile acids or inhibits the esterification of cholesterol. These may include, for example, cholesterol-7a hydroxylase activator or Acyl-CoA acyl transferase inhibitor. In a further preferred embodiment, a combination of phytosterols may be included with the policosanol-containing sugar cane juice.
[0033] A method for reducing blood serum cholesterol levels or preventing elevated blood cholesterol levels is provided. The method comprises administering or ingesting an effective amount of a composition comprising sugar cane juice. The method of the invention is effective in lowering total cholesterol, decreasing LDL-cholesterol and/or increasing HDL-cholesterol.
The composition is preferably provided in the form of a food or beverage. The composition is preferably administered orally. A daily dose of the composition comprises from about 1 to about 2000 mg policosanol, preferably at least 10 mg policosanol, more preferably at least 20 mg, most preferably at least 40 mg policosanol. Alternatively, the composition may administered as a syrup.
The composition can also be administered intravenously as a drip.
[0034] The method of the invention optionally includes the co-administration of one or more active agents in addition to the sugar cane juice. The additional active agents may be provided in the same composition as the - s -sugar cane juice or in a separate composition. An additional active agent for use in the invention is preferably an active agent that reduces LDL
cholesterol or increases HDL-cholesterol. A preferred additional active agent is a phytosterol.
[0035] As shown in Figures 1 to 3 and discussed in greater detail in the Examples below, a daily dose of sugar cane juice significantly decreases overall cholesterol and specifically LDL cholesterol while causing an increase in HDL levels. Figure 1 illustrates that mean total cholesterol levels were decreased after the treatment as compared to the baseline score. Figure 2 illustrates that mean HDL levels increase as compared to the baseline after ingestion of sugar cane juice. Figure 3 illustrates that the most significant effect the reduction of LDL scores when the levels post treatment are compared to the baseline levels.
[0036] The present invention demonstrates that a composition comprising sugar cane juice can have significant effects on cardiovascular health as measured by serum cholesterol levels. Without being limited by explanation, it is likely that these effects are due to policosanols in the sugar cane juice.
Of course, it is considered that other heart healthy components could also be present in the sugar cane juice. The results presented herein demonstrate that sugar cane juice can contain clinically relevant amounts of policosanol.
Daily administration of policosanol-containing sugar cane juice has been shown to be safe and tolerable in humans and lowers total cholesterol and LDL-cholesterol. Ingestion of sugar cane juice also elevates HDL levels.
Policosanol may exert its effects by regulating the activity of HMG-CoA
reductase and LDL-C processing. There is also some evidence that policosanol can inhibit in vitro platelet aggregation. Furthermore, policosanol has been associated with reduced in vivo oxidative stress in some studies and has been associated with an increase in exercise endurance in patients with intermittent claudication and coronary artery disease. These results indicate that compositions and methods including sugar cane juice as a source of policosanois will provide significant health and economic benefits.
[0037] The present invention also provides a method of preparing sugar cane juice that preserves health promoting active agents. In traditional methods, high temperatures are used in the extraction process. In the method of the present invention, the temperature of the processing system is maintained below 150 C, preferably below 120 C, more preferably below 105 C. Sugar can juice prepare according to the present invention contains policosanols that would normally be lost through a high temperature process.
[0038] The above disclosure generally describes the present invention. It is believed that one of ordinary skill in the art can, using the preceding description, make and use the compositions and practice the methods of the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely to illustrate preferred embodiments of the present invention and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Other generic configurations will be apparent to one skilled in the art. All journal articles and other documents such as patents or patent applications referred to herein are hereby incorporated by reference.
EXAMPLES
[0039] Although specific terms have been used in these examples, such terms are intended in a descriptive sense and not for purposes of limitation.
Methods of biochemistry and chemistry referred to but not explicitly described in the disclosure and these examples are reported in the scientific literature and are well known to those skilled in the art.
Example 1. Analysis of Sugar cane iuice for policosanols.
The fatty acid content of a sample of sugar cane juice was determined by gas chromatography with flame ionization detection. The concentration of the policosanol marker compound (octacosanol) was calibrated using a sample from Sigma chemicals and the results for the other fatty alcohols were based on the octacosanol calibration. Standards for tetracosanol, hexacosanol and triacosanol were used as retention time markers. Results for dotriacontanol and tetratricontanol were based on predicted relative retention times. The results are shown in Table 1 below:
ALPHA Sample #04-2653 Policosanol by GC-FID Result Units I.Octacosanol by GC-FID
Octacosanol <0.5 % wt/wt Octacosanol (D) <0.5 % wt/wt II. Fatty Alcohols Identified by Comparison with Standards Tetracosanol <0.5 % wt/wt Tetracosanol (D) <0.5 % wt/wt Hexacosanol <0.5 % wt/wt Hexacosanol(D) <0.5 % wt/wt Triacontanol <0.5 % wt/wt Triacontanol (D) III. Tentatively Identified Fatty Alcohols Dotriacontanol <0.5 % wt/wt Dotriacontanol (D) <0.5 % wt/wt Tetratriacontanol 2.2 % wt/wt Tetratriacontanol (D) 2.4 % wt/wt Each result is the average of two injections per sample preparation.
(D) = Duplicate sample preparation for internal quality check.
Example 2. Effect of daily sugar cane iuice on cholesterol levels.
[0040] Twenty-three male and female participants of all ethnic backgrounds from the ages of 19-62 were randomly selected without screening. Subjects were instructed to fast on the mornings that blood was drawn, which occurred between the hours of 7:00-9:30 a.m. Conducting the investigation as a single-blind study, an initial blood sample was taken and tested for complete lipid panels. Each participant was given two bottles of sugar can juice product containing 100 mg of policosanois per 5g serving. Each subject was instructed to ingest 1 teaspoon (5g) each day for an eight-week duration. A
final blood sample was then drawn for lipid panels. A within groups dependent T-test on difference scores was run on the data to ascertain the effects on total cholesterol, HDL cholesterol, and LDL cholesterol.
[0041] A total of 23 participants chose to participate in this study; however, subjects were disqualified based on the following post-test questionnaire responses: noncompliance to take the product every day for the full eight week duration (3 subjects) - and in absentia during the final blood drawing (2 subjects). No side effects were reported for any participants.
[0042] For the remaining qualifying subjects, Table 2 below displays the mean values for total cholesterol, HDL cholesterol, and LDL cholesterol for the baseline and treatment groups. The percent increase or decrease was also noted for both trials. The mean values of total cholesterol for the baseline and treatment scores were 208.00 and 201.11, respectively, indicating a 3.31 % decrease from baseline to treatment scores. The mean values of HDL
cholesterol for the baseline and treatment scores were 52.89 and 57.67, respectively, signifying an increase of 8.29% from baseline to treatment scores. The mean values of LDL cholesterol for the baseline and treatment scores were 130.39 and 117.28, respectively, showing a 10.40% decrease from baseline to treatment scores.
Measurement Mean Baseline Mean Treatment Percent Change Score Score Total Cholesterol 208.00 201.11 -3.31%
(mg/dL) HDL Cholesterol 52.89 57.67 +8.29%
(mg/dL) LDL Cholesterol 130.89 117.28 -10.40%
(mg/dL) [0043] Figure 1 shows the mean cholesterol for the baseline and treatment trials. Standard error bars show some overlap between trials; however, the dependent samples t-Test showed a significant decrease in total cholesterol in the treatment reading over the baseline reading: t (17) = 2.09, p < 0.05.
Mean total cholesterol decreased 3.31 % from the baseline reading to the treatment reading.
[0044] Figure 2 shows the mean HDL cholesterol for the baseline and treatment trials. Standard error bars show little overlap in the data, and the dependent samples t-Test reported the treatment scores having significantly increased HDL cholesterol than baseline scores: t(17) = 2.07, p < 0.05. Mean HDL cholesterol increased 8.29% from the baseline reading to the treatment reading.
[0045] Figure 3 displays the mean LDL cholesterol for the baseline and treatment scores. Standard error bars show little overlap in the data, and the dependent samples t-Test reported a significant decrease in LDL cholesterol for the treatment scores over the baseline scores: t(17) = 3.01, p < 0.05.
Mean LDL cholesterol showed a 10.40% decrease from the baseline reading to the treatment reading.
[0046] All citations are hereby incorporated by reference.
[0047] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
[0031 ] One example of a preferred agent for use in the food product is phytosterol. Phytosterols are steroids derived from plants, yeast or fungi.
They are preferably obtained from whole plants or parts thereof such as leaves, stalks, roots, shoots, rhizomes, fruits, kernels, husks, etc.
Naturally occurring compositions or extracts may be used. The term "phytosterol" is used herein to refer to plant sterols and plant stanols that differ from cholesterol in that the side chain at position 17 contains a double bond and/or an additional methyl, ethyl or ethylidene group. The term also encompasses any analogues, derivatives or combinations thereof.
[0032] Phytosterols are similar to cholesterol and compete with cholesterol to get absorbed into the body. In the present invention, the phytosterols may be combined with lecithin to enhance their solubility and absorption. A mixture of more than one phytosterol may be included. In one embodiment, the phytosterol is one that reduces cholesterol absorption in the intestine. In another embodiment, the phytosterol inhibits cholesterol biosynthesis. An exemplary phytosterol composition for use in the present invention could comprise a composition that inhibits the enzyme, 3-hydroxy-3-methylguaryl coenzyme A reductase (HMG+CoA reductase). In yet another embodiment, a phytosterol composition capable of increasing cholesterol metabolism is provided. The phytosterol increases the conversion of cholesterol into bile acids or inhibits the esterification of cholesterol. These may include, for example, cholesterol-7a hydroxylase activator or Acyl-CoA acyl transferase inhibitor. In a further preferred embodiment, a combination of phytosterols may be included with the policosanol-containing sugar cane juice.
[0033] A method for reducing blood serum cholesterol levels or preventing elevated blood cholesterol levels is provided. The method comprises administering or ingesting an effective amount of a composition comprising sugar cane juice. The method of the invention is effective in lowering total cholesterol, decreasing LDL-cholesterol and/or increasing HDL-cholesterol.
The composition is preferably provided in the form of a food or beverage. The composition is preferably administered orally. A daily dose of the composition comprises from about 1 to about 2000 mg policosanol, preferably at least 10 mg policosanol, more preferably at least 20 mg, most preferably at least 40 mg policosanol. Alternatively, the composition may administered as a syrup.
The composition can also be administered intravenously as a drip.
[0034] The method of the invention optionally includes the co-administration of one or more active agents in addition to the sugar cane juice. The additional active agents may be provided in the same composition as the - s -sugar cane juice or in a separate composition. An additional active agent for use in the invention is preferably an active agent that reduces LDL
cholesterol or increases HDL-cholesterol. A preferred additional active agent is a phytosterol.
[0035] As shown in Figures 1 to 3 and discussed in greater detail in the Examples below, a daily dose of sugar cane juice significantly decreases overall cholesterol and specifically LDL cholesterol while causing an increase in HDL levels. Figure 1 illustrates that mean total cholesterol levels were decreased after the treatment as compared to the baseline score. Figure 2 illustrates that mean HDL levels increase as compared to the baseline after ingestion of sugar cane juice. Figure 3 illustrates that the most significant effect the reduction of LDL scores when the levels post treatment are compared to the baseline levels.
[0036] The present invention demonstrates that a composition comprising sugar cane juice can have significant effects on cardiovascular health as measured by serum cholesterol levels. Without being limited by explanation, it is likely that these effects are due to policosanols in the sugar cane juice.
Of course, it is considered that other heart healthy components could also be present in the sugar cane juice. The results presented herein demonstrate that sugar cane juice can contain clinically relevant amounts of policosanol.
Daily administration of policosanol-containing sugar cane juice has been shown to be safe and tolerable in humans and lowers total cholesterol and LDL-cholesterol. Ingestion of sugar cane juice also elevates HDL levels.
Policosanol may exert its effects by regulating the activity of HMG-CoA
reductase and LDL-C processing. There is also some evidence that policosanol can inhibit in vitro platelet aggregation. Furthermore, policosanol has been associated with reduced in vivo oxidative stress in some studies and has been associated with an increase in exercise endurance in patients with intermittent claudication and coronary artery disease. These results indicate that compositions and methods including sugar cane juice as a source of policosanois will provide significant health and economic benefits.
[0037] The present invention also provides a method of preparing sugar cane juice that preserves health promoting active agents. In traditional methods, high temperatures are used in the extraction process. In the method of the present invention, the temperature of the processing system is maintained below 150 C, preferably below 120 C, more preferably below 105 C. Sugar can juice prepare according to the present invention contains policosanols that would normally be lost through a high temperature process.
[0038] The above disclosure generally describes the present invention. It is believed that one of ordinary skill in the art can, using the preceding description, make and use the compositions and practice the methods of the present invention. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely to illustrate preferred embodiments of the present invention and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Other generic configurations will be apparent to one skilled in the art. All journal articles and other documents such as patents or patent applications referred to herein are hereby incorporated by reference.
EXAMPLES
[0039] Although specific terms have been used in these examples, such terms are intended in a descriptive sense and not for purposes of limitation.
Methods of biochemistry and chemistry referred to but not explicitly described in the disclosure and these examples are reported in the scientific literature and are well known to those skilled in the art.
Example 1. Analysis of Sugar cane iuice for policosanols.
The fatty acid content of a sample of sugar cane juice was determined by gas chromatography with flame ionization detection. The concentration of the policosanol marker compound (octacosanol) was calibrated using a sample from Sigma chemicals and the results for the other fatty alcohols were based on the octacosanol calibration. Standards for tetracosanol, hexacosanol and triacosanol were used as retention time markers. Results for dotriacontanol and tetratricontanol were based on predicted relative retention times. The results are shown in Table 1 below:
ALPHA Sample #04-2653 Policosanol by GC-FID Result Units I.Octacosanol by GC-FID
Octacosanol <0.5 % wt/wt Octacosanol (D) <0.5 % wt/wt II. Fatty Alcohols Identified by Comparison with Standards Tetracosanol <0.5 % wt/wt Tetracosanol (D) <0.5 % wt/wt Hexacosanol <0.5 % wt/wt Hexacosanol(D) <0.5 % wt/wt Triacontanol <0.5 % wt/wt Triacontanol (D) III. Tentatively Identified Fatty Alcohols Dotriacontanol <0.5 % wt/wt Dotriacontanol (D) <0.5 % wt/wt Tetratriacontanol 2.2 % wt/wt Tetratriacontanol (D) 2.4 % wt/wt Each result is the average of two injections per sample preparation.
(D) = Duplicate sample preparation for internal quality check.
Example 2. Effect of daily sugar cane iuice on cholesterol levels.
[0040] Twenty-three male and female participants of all ethnic backgrounds from the ages of 19-62 were randomly selected without screening. Subjects were instructed to fast on the mornings that blood was drawn, which occurred between the hours of 7:00-9:30 a.m. Conducting the investigation as a single-blind study, an initial blood sample was taken and tested for complete lipid panels. Each participant was given two bottles of sugar can juice product containing 100 mg of policosanois per 5g serving. Each subject was instructed to ingest 1 teaspoon (5g) each day for an eight-week duration. A
final blood sample was then drawn for lipid panels. A within groups dependent T-test on difference scores was run on the data to ascertain the effects on total cholesterol, HDL cholesterol, and LDL cholesterol.
[0041] A total of 23 participants chose to participate in this study; however, subjects were disqualified based on the following post-test questionnaire responses: noncompliance to take the product every day for the full eight week duration (3 subjects) - and in absentia during the final blood drawing (2 subjects). No side effects were reported for any participants.
[0042] For the remaining qualifying subjects, Table 2 below displays the mean values for total cholesterol, HDL cholesterol, and LDL cholesterol for the baseline and treatment groups. The percent increase or decrease was also noted for both trials. The mean values of total cholesterol for the baseline and treatment scores were 208.00 and 201.11, respectively, indicating a 3.31 % decrease from baseline to treatment scores. The mean values of HDL
cholesterol for the baseline and treatment scores were 52.89 and 57.67, respectively, signifying an increase of 8.29% from baseline to treatment scores. The mean values of LDL cholesterol for the baseline and treatment scores were 130.39 and 117.28, respectively, showing a 10.40% decrease from baseline to treatment scores.
Measurement Mean Baseline Mean Treatment Percent Change Score Score Total Cholesterol 208.00 201.11 -3.31%
(mg/dL) HDL Cholesterol 52.89 57.67 +8.29%
(mg/dL) LDL Cholesterol 130.89 117.28 -10.40%
(mg/dL) [0043] Figure 1 shows the mean cholesterol for the baseline and treatment trials. Standard error bars show some overlap between trials; however, the dependent samples t-Test showed a significant decrease in total cholesterol in the treatment reading over the baseline reading: t (17) = 2.09, p < 0.05.
Mean total cholesterol decreased 3.31 % from the baseline reading to the treatment reading.
[0044] Figure 2 shows the mean HDL cholesterol for the baseline and treatment trials. Standard error bars show little overlap in the data, and the dependent samples t-Test reported the treatment scores having significantly increased HDL cholesterol than baseline scores: t(17) = 2.07, p < 0.05. Mean HDL cholesterol increased 8.29% from the baseline reading to the treatment reading.
[0045] Figure 3 displays the mean LDL cholesterol for the baseline and treatment scores. Standard error bars show little overlap in the data, and the dependent samples t-Test reported a significant decrease in LDL cholesterol for the treatment scores over the baseline scores: t(17) = 3.01, p < 0.05.
Mean LDL cholesterol showed a 10.40% decrease from the baseline reading to the treatment reading.
[0046] All citations are hereby incorporated by reference.
[0047] The present invention has been described with regard to one or more embodiments. However, it will be apparent to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as defined in the claims.
Claims (36)
1. A method of lowering LDL-cholesterol or increasing HDL-cholesterol comprising administering to a mammal a daily dose of at least 1 g of sugar cane juice for at least one week.
2. A method of lowering LDL-cholesterol or increasing HDL-cholesterol comprising administering to a mammal a daily dose of at least 1 g of sugar cane juice for at least two weeks.
3. A method of lowering LDL-cholesterol or increasing HDL-cholesterol comprising administering to a mammal a daily dose of at least 1 g of sugar cane juice for at least four weeks.
4. A method of lowering LDL-cholesterol or increasing HDL-cholesterol comprising administering to a mammal a daily dose of at least 1 g of sugar cane juice for at least six weeks.
5. A method according to claim 1, wherein said sugar cane juice comprises policosanol.
6. A method according to claim 1, wherein said sugar cane juice is provided in a composition comprising at least one additional agent selected from the group consisting of: amino acids, carbohydrates, vitamins, minerals, polysaturated fatty acids, flavenols, sterols, psyllium, garlic, gugulipid, anti-oxidants, folic acid, beta-carotene, lycopene, red yeast rice extract, natural and synthetic flavors, colors, preservatives, stabilizers, emulsifiers, leavening agents and combinations thereof.
7. A method according to claim 6 wherein said additional agent is a phytosterol.
8. A method according to claim 7 wherein said phytosterol is present in an amount from about 0.01 to about 20 g per day.
9. A method according to claim 7 wherein said phytosterol is present in an amount of at least 0.1 g.
10. A method according to claim 7 wherein said phytosterol is present in an amount of at least 1 g.
11. A method according to any one of the previous claims wherein said sugar cane juice is provided for oral consumption in a food product selected from the group consisting of: cake, cookie, candy, energy bar, pudding, yogurt, frozen dessert, pie, pastry, jam, jelly, pie filling, donuts, sauces, gravies, beverages, including alcohol beverages, chewing gum, and other processed foods.
12. A method according to claim 1 wherein the daily dose comprises at least 3 g of sugar cane juice.
13. A method according to claim 1 wherein the daily dose comprises at least 5 g of sugar cane juice.
14. A method according to claim 6 wherein the daily dose of sugar cane juice comprises at least 0.1 mg of policosanol.
15. A method according to claim 14 wherein the daily dose of sugar cane juice comprises at least 0.1 mg of policosanol.
16. A method according to claim 14 wherein the daily dose of sugar cane juice comprises at least 1 mg of policosanol.
17. A method according to claim 14 wherein the daily dose of sugar cane juice comprises at least 4 mg of policosanol.
18. A method according to claim 1 wherein the sugar cane juice is provided in a format for intravenous administration.
19. A method according to claim 1 wherein the sugar cane juice is extracted using a process wherein the temperature is maintained at less than 120°C.
20. A method according to claim 1 wherein the sugar cane juice is extracted using a process wherein the temperature is maintained at less than 105°C.
21. A composition for lowering LDL cholesterol, said composition comprising sugar cane juice having at least 0.1 mg policosanol.
22. A composition according to claim 21 wherein the sugar can juice comprises at least 0.5 mg policosanol.
23. A composition according to claim 21 wherein the sugar can juice comprises at least 1 mg policosanol.
24. A composition according to claim 21 wherein the sugar can juice comprises at least 2 mg policosanol.
25. A composition according to claim 21 wherein the sugar can juice comprises at least 4 mg policosanol.
26. A composition according to claim 18, wherein said composition includes an additional agent selected from the group consisting of dietary fiber, protein, amino acids, carbohydrates, vitamins, minerals, fats, flavenols, sterols, psyllium, garlic, gugulipid, anti-oxidants, folic acid, polyunsaturated fatty acids, omega-3 fatty acids, beta-carotene, lycopene, red yeast rice extract, synthetic flavors, colors, preservatives, stabilizers, emulsifiers, and leavening agents.
27. A composition according to claim 21, wherein said additional agent is a phytosterol.
28. A composition according to claim 26 wherein the phytosterol is provided in an amount of at least 0.1 g.
29. A composition according to claim 26 wherein the phytosterol is provided in an amount of at least 1 g.
30. A composition according to claim 26 wherein the phytosterol is provided in an amount of at least 5 g.
31. An LDL-lowering food product comprising sugar cane juice as an active agent, whereby daily consumption of the food product results in a decrease in LDL levels relative to the baseline level.
32. A food product comprising sugar cane juice as an agent to increase HDL levels.
33. Use of sugar cane juice as an agent for the treatment or prevention of cardiovascular disease.
34. Use according to claim 31, wherein said juice comprises at least 1 mg policosanol.
35. A method of preparing sugar cane juice containing policosanols comprising extracting the juice from sugar cane at a temperature of less than 120°C.
36. A method of preparing sugar cane juice containing policosanols comprising extracting the juice from sugar cane at a temperature of less than or equal to 105°C.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002544227A CA2544227A1 (en) | 2006-04-20 | 2006-04-20 | Food product containing policosanols |
PCT/CA2007/000697 WO2007121584A1 (en) | 2006-04-20 | 2007-04-20 | Food product containing policosanols |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002544227A CA2544227A1 (en) | 2006-04-20 | 2006-04-20 | Food product containing policosanols |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2544227A1 true CA2544227A1 (en) | 2007-10-20 |
Family
ID=38606748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002544227A Abandoned CA2544227A1 (en) | 2006-04-20 | 2006-04-20 | Food product containing policosanols |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2544227A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10159268B2 (en) | 2013-02-08 | 2018-12-25 | General Mills, Inc. | Reduced sodium food products |
-
2006
- 2006-04-20 CA CA002544227A patent/CA2544227A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10159268B2 (en) | 2013-02-08 | 2018-12-25 | General Mills, Inc. | Reduced sodium food products |
US11540539B2 (en) | 2013-02-08 | 2023-01-03 | General Mills, Inc. | Reduced sodium food products |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11571479B2 (en) | Nutritional composition | |
US6365176B1 (en) | Nutritional supplement for patients with type 2 diabetes mellitus for lipodystrophy | |
KR20190007412A (en) | And compositions for improving weight loss and cardiovascular health after eating and exercise | |
US20070104805A1 (en) | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
KR20180043251A (en) | Compositions and methods for acutely boosting nitric oxide levels | |
JP2008509213A (en) | Food products for diabetics | |
JP7473516B2 (en) | A formula that promotes gut health | |
US20110177175A1 (en) | Dietary fiber compositions | |
EP3590356A1 (en) | Composition for controlling and reducing blood cholesterol levels | |
JP2010539077A (en) | Pomegranate extract, nutritional product containing the extract and use thereof | |
US20120177623A1 (en) | Compositions for Boosting Metabolism, Assisting Weight Loss, and Promoting Cardiovascular Health | |
CN105394182A (en) | Nutritional steamed stuffed bun with blood sugar reducing and heart and cerebral vessel health promoting efficacy | |
JP6335508B2 (en) | Growth hormone secretagogue | |
US20070248621A1 (en) | Food product containing policosanols | |
CN107496469A (en) | Sleep quality improver | |
JP2016199491A (en) | Mood state improver | |
US20200113982A1 (en) | Composition and Uses Thereof | |
US8557236B2 (en) | Cardiovascular support supplement and compositions and methods thereof | |
WO2007121584A1 (en) | Food product containing policosanols | |
JP2008133272A (en) | Cpt activity enhancing agents and food and beverages | |
JP2019054791A (en) | Fatigue improving composition | |
CA2544227A1 (en) | Food product containing policosanols | |
Baragi et al. | Neutraceuticals in Ayurveda with special reference to Avaleha Kalpana | |
US20080161413A1 (en) | Agent for increasing adiponectin in blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |